前瞻性研究:氧增强MRI T1映射预测肺移植移植物丢失
这项单中心、纵向、前瞻性研究纳入141例临床稳定的双肺移植受者,在移植后6-12个月及基线MRI后2.5年随访时行氧增强MRI T1映射,发现基线及随访时的氧增强MRI参数可预测5.6年观察期内CLAD相关移植物丢失,其中delta T1 OV是最一致的预测指标。
要点
- 移植后6-12个月氧增强MRI的delta T1中位数、四分位离散系数和delta T1 OV可预测5.6年内CLAD相关移植物丢失。
- 随访时OTF、delta T1 OV和FEV1较基线的变化百分比均与更差的生存相关。
- delta T1 OV是预测未来移植物丢失最一致的指标。
核心结论
- 氧增强MRI参数可预测肺移植后6-12个月及基线MRI后2.5年时的CLAD相关移植物丢失,delta T1 OV是最一致的预测指标。
研究设计与样本
- 单中心、纵向、前瞻性研究,2013年8月至2018年12月纳入141例临床稳定的双肺移植受者(移植后6-12个月),其中132例进行分析,基线MRI后2.5年随访,采用Kaplan-Meier生存分析和Cox比例风险模型比较各生物标志物至CLAD相关移植物丢失的时间。
诊断标准与关键数值
- 基线时,delta T1中位数预测5.6年内移植物丢失的HR为3.50(95%CI:1.0, 9.4;P = .048)。
- 基线时,四分位离散系数预测5.6年内移植物丢失的HR为3.43(95%CI:1.1, 8.7;P = .03)。
- 基线时,delta T1氧合体积预测5.6年内移植物丢失的HR为3.07(95%CI:1.18, 7.22;P = .02)。
- 基线时,OTF(P = .18)和肺功能(P = .32)未预测5.6年内移植物丢失。
- 随访时(91例稳定 vs 11例移植物丢失),OTF变化(HR,11.1;95%CI:2.5, 75.9;P = .001)、delta T1 OV变化(HR,6.47;95%CI:1.52, 27.53;P = .01)和FEV1变化(HR,7.94;95%CI:2.16, 27.4;P = .003)均预测更差的生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Purpose To investigate the predictive efficacy of oxygen-enhanced MRI T1 mapping parameters for detecting chronic lung allograft dysfunction (CLAD)-related graft loss at 6-12 months and for an additional 2.5 years following pulmonary transplant over a 5.6-year observational interval. Materials and Methods In this single-center, longitudinal, and prospective study conducted between August 2013 and December 2018, parameters from oxygen-enhanced MRI T1 mapping (including oxygen transfer function [OTF], delta T1 oxygenated volume [OV]) were acquired from 141 clinically stable double-lung transplant recipients (6-12 months after transplant) and follow-up (2.5 years after baseline MRI). Applying Kaplan-Meier survival analysis and Cox proportional hazards model, all biomarkers were compared regarding the time to CLAD-related graft loss as the primary outcome measure. Results Participants (n = 141; mean age, 50 years ± 13 [SD], 76 men, 65 women) underwent baseline MRI, of which 132 were analyzed. Over the following 5.6-year observational period, 24 (18%) participants experienced graft loss related to CLAD. At baseline, oxygen-enhanced MRI parameters predicted graft loss within 5.6 years: delta T1 median (hazard ratio [HR], 3.50; 95% CI: 1.0, 9.4; P = .048), quartile coefficient of dispersion (HR, 3.43; 95% CI: 1.1, 8.7; P = .03), and delta T1 oxygenated volume (HR, 3.07; 95% CI 1.18, 7.22; P = .02), while OTF (P = .18) and spirometry (P = .32) did not. At follow-up (91 stable vs 11 graft loss), all parameter changes (follow-up/baseline value × 100 [%baseline]) predicted poorer survival: OTF (HR, 11.1; 95% CI: 2.5, 75.9; P = .001), delta T1 OV (HR, 6.47; 95% CI: 1.52, 27.53; P = .01), and forced expiratory volume in 1 second from spirometry (HR, 7.94; 95% CI: 2.16, 27.4; P = .003). Conclusion Oxygen-enhanced MRI parameters predict CLAD-related graft loss at 6-12 months following lung transplant and 2.5 years after baseline MRI. Delta T1 OV was the most consistent predictor of future graft loss. Keywords: MRI, Lung, Transplantation Supplemental material is available for this article. © RSNA, 2025.
引用
- Speth M, Kaireit TF, Gutberlet M, et al. Predicting Pulmonary Graft Loss Using Oxygen-enhanced MRI T1 Mapping in a Prospective Study. Radiol Cardiothorac Imaging. 2025. PMID: 40838823. doi:10.1148/ryct.240274
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。